DEFA14A: Amicus Therapeutics Reports Strong Preliminary 2025 Revenues

Amicus Therapeutics provides preliminary unaudited financial results for 2025, showing robust product revenue growth ahead of its acquisition by BioMarin.

Summary

• Amicus Therapeutics estimates approximately $294 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Total net product revenues for the year ended December 31, 2025, are estimated at approximately $634 million.
• Galafold revenues contributed approximately $522 million to the total net product revenues.
• Pombiliti + Opfolda revenues amounted to approximately $112 million.
• These financial estimates are preliminary, unaudited, and subject to normal accounting and closing procedures.
• The preliminary financial information was provided to BioMarin Pharmaceutical Inc. (Parent) in connection with the proposed acquisition of Amicus.
• A preliminary proxy statement was filed on January 21, 2026, for the proposed acquisition, with a definitive version to be sent to stockholders for approval.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong preliminary revenue figures for key products and a healthy cash position, all within the context of a pending acquisition by a larger entity. The acquisition itself, if successful, offers a clear exit strategy and value realization for shareholders. The primary cautionary notes are the preliminary nature of the financials and the inherent risks associated with any merger.

Positives

• Strong estimated total net product revenues of approximately $634 million for the year ended December 31, 2025.
• Robust estimated revenue from Galafold at approximately $522 million.
• Significant estimated revenue contribution from Pombiliti + Opfolda at approximately $112 million.
• Healthy cash position with approximately $294 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

Negatives

• The financial estimates are preliminary and unaudited, meaning they are subject to change and have not been reviewed by an independent accounting firm.
• The estimates do not present all information necessary for a full understanding of Amicus's results of operations and should not be viewed as a substitute for full financial statements.

Risks

• Uncertainty regarding the consummation of the Transaction and its financing in the anticipated timeframe, if at all.
• The possibility of an event, change, or circumstance leading to the termination of the Agreement and Plan of Merger.
• Uncertainties related to obtaining shareholder approval for the acquisition.
• The potential for competing acquisition proposals to be made.
• Risk that various closing conditions for the Transaction may not be satisfied or waived, including governmental entity approval.
• Potential adverse effects of the Transaction on relationships with employees, customers, suppliers, business partners, or governmental entities, including employee retention.
• Difficulty in predicting the timing or outcome of regulatory approvals or actions.
• Impact of competitive products and pricing on Amicus's business.
• Risk that BioMarin may not realize the potential benefits of the Transaction, including integration difficulties or higher-than-expected costs.
• Disruption of management's time from ongoing business operations due to the Transaction.
• Risks that the Transaction disrupts current plans and operations.
• Challenges in obtaining and maintaining adequate coverage and reimbursement for Amicus products.
• Changes in Amicus's business during the period between the announcement and closing of the Transaction.
• Any legal proceedings and/or regulatory actions that may be instituted related to the Transaction.
• Other business effects, including industry, economic, or political conditions outside of the companies' control.
• Costs and expenses related to the Transaction, and actual or contingent liabilities.
• The effects of the Transaction (or its announcement) on Amicus's and BioMarin's stock price and/or operating results.

Future Outlook

The future outlook is primarily centered on the successful completion of the proposed acquisition by BioMarin Pharmaceutical Inc. This involves obtaining shareholder approval and satisfying various closing conditions, including regulatory clearances. The preliminary financial results for 2025 indicate strong performance leading into the acquisition, but these figures are subject to final audit and may differ from actual results.

Management Comments

• Amicus management is responsible for the preparation of the preliminary estimates of cash, cash equivalents, marketable securities, and product revenues.

Industry Context

This announcement occurs within the biopharmaceutical industry, specifically in the rare disease sector where Amicus Therapeutics specializes. The acquisition by BioMarin Pharmaceutical Inc., a larger player also focused on rare diseases, reflects ongoing consolidation and strategic alignment within the industry to expand product portfolios and market reach. The strong preliminary revenue figures for Amicus's key products, Galafold and Pombiliti + Opfolda, highlight the commercial success of therapies addressing unmet needs in rare genetic conditions.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on the proposed acquisition and are urged to read the definitive proxy statement for important information regarding the transaction and their interests.
• Employees: The transaction carries a risk that it could adversely affect employee retention.
• Customers and Suppliers: Relationships with these parties could be affected by the transaction.
• Creditors: BioMarin is funding the acquisition via a private placement of senior notes, which impacts the capital structure of the combined entity.

Next Steps

• Amicus stockholders are urged to read the definitive proxy statement and other relevant documents filed with the SEC regarding the proposed Transaction.
• Amicus stockholders will need to vote on the proposed acquisition by BioMarin Pharmaceutical Inc. at a special meeting.

Key Dates

Recommendation

Given the pending acquisition by BioMarin Pharmaceutical Inc., the stock price of Amicus Therapeutics is likely to trade closely to the agreed-upon acquisition price, minus any discount reflecting the time to close and the risk of the deal not completing. For investors, holding the stock until the acquisition closes is generally the recommended strategy to realize the merger consideration, assuming the deal is expected to proceed as planned. New fundamental analysis is less relevant as the company's independent future is limited.

Keywords

Amicus Therapeutics, BioMarin Pharmaceutical, Acquisition, Merger, Preliminary Financials, Product Revenue, Galafold, Pombiliti, Opfolda, Rare Disease, Biotechnology, SEC Filing, Form 8-K